DKK1 and neoplasm: This loss of efficacy was seen with both tumours from CC‐LP‐1 cells expressing endogenous levels of DKK1 as well as from CC‐LP‐1 genetically modified to overexpress the protein, and demonstrates that the mechanism of action for anti‐DKK1 monoclonal therapeutics requires an intact adaptive immune system.